BR112023019364A2 - Composição para geração de imagens de contraste de câncer - Google Patents
Composição para geração de imagens de contraste de câncerInfo
- Publication number
- BR112023019364A2 BR112023019364A2 BR112023019364A BR112023019364A BR112023019364A2 BR 112023019364 A2 BR112023019364 A2 BR 112023019364A2 BR 112023019364 A BR112023019364 A BR 112023019364A BR 112023019364 A BR112023019364 A BR 112023019364A BR 112023019364 A2 BR112023019364 A2 BR 112023019364A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- image generation
- contrast image
- cancer contrast
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
composição para geração de imagens de contraste de câncer. um objetivo da presente invenção é fornecer um agente de contraste capaz de identificar especificamente um tecido canceroso. quando é administrada uma composição para geração de imagens de contraste de câncer contendo um composto da presente invenção, um tecido canceroso pode ser visualizado com luz no infravermelho próximo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021049967 | 2021-03-24 | ||
PCT/JP2022/013353 WO2022202863A1 (ja) | 2021-03-24 | 2022-03-23 | がん造影用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023019364A2 true BR112023019364A2 (pt) | 2023-12-26 |
Family
ID=83397294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023019364A BR112023019364A2 (pt) | 2021-03-24 | 2022-03-23 | Composição para geração de imagens de contraste de câncer |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240181087A1 (pt) |
EP (1) | EP4316529A1 (pt) |
JP (1) | JPWO2022202863A1 (pt) |
KR (1) | KR20230159591A (pt) |
CN (1) | CN117042811A (pt) |
AU (1) | AU2022243280A1 (pt) |
BR (1) | BR112023019364A2 (pt) |
CA (1) | CA3213157A1 (pt) |
MX (1) | MX2023011153A (pt) |
WO (1) | WO2022202863A1 (pt) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005220045A (ja) * | 2004-02-04 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | 蛍光造影剤 |
EP2530093B1 (en) * | 2010-01-28 | 2018-11-21 | National UniversityCorporation Mie University | Indocyanine compound, synthesis method thereof, purification method thereof, diagnostic composition using indocyanine compound, and device for measuring in vivo kinetics and device for visualizing circulation using diagnostic composition |
JP2017128532A (ja) * | 2016-01-20 | 2017-07-27 | キヤノン株式会社 | 光学イメージング用造影剤の製造方法、及び光学イメージング用造影剤 |
-
2022
- 2022-03-23 CA CA3213157A patent/CA3213157A1/en active Pending
- 2022-03-23 EP EP22775645.9A patent/EP4316529A1/en active Pending
- 2022-03-23 WO PCT/JP2022/013353 patent/WO2022202863A1/ja active Application Filing
- 2022-03-23 MX MX2023011153A patent/MX2023011153A/es unknown
- 2022-03-23 CN CN202280023289.1A patent/CN117042811A/zh active Pending
- 2022-03-23 US US18/282,829 patent/US20240181087A1/en active Pending
- 2022-03-23 KR KR1020237036389A patent/KR20230159591A/ko unknown
- 2022-03-23 AU AU2022243280A patent/AU2022243280A1/en active Pending
- 2022-03-23 JP JP2023509227A patent/JPWO2022202863A1/ja active Pending
- 2022-03-23 BR BR112023019364A patent/BR112023019364A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023011153A (es) | 2023-10-05 |
CN117042811A (zh) | 2023-11-10 |
US20240181087A1 (en) | 2024-06-06 |
CA3213157A1 (en) | 2022-09-29 |
KR20230159591A (ko) | 2023-11-21 |
AU2022243280A1 (en) | 2023-09-28 |
EP4316529A1 (en) | 2024-02-07 |
WO2022202863A1 (ja) | 2022-09-29 |
JPWO2022202863A1 (pt) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018012090A2 (pt) | visualização 3d durante a cirurgia com exposição à radiação reduzida | |
BR112018011854A2 (pt) | dispositivo para tratamento oral | |
BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
BR112012033776A2 (pt) | composição,e, método de exame de raios-x. | |
Herr | Retracted: randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors | |
BRPI0600218A (pt) | instrumento médico dotado de eletrodo de tratamento médico | |
SV2017005530A (es) | Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida | |
BR112021006458A2 (pt) | composto de isoindolina, seu método de preparação, composição farmacêutica e uso | |
BR112019024717A2 (pt) | nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas | |
BRPI0821007A8 (pt) | Sistemas para rastrear um instrumento médico durante um procedimento intervencional e para minimizar a dose de radiação durante rastreamento de um instrumento médico, e, método para rastrear um instrumento médico | |
AR107529A1 (es) | Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento | |
BR112015004244A2 (pt) | composição médica oralmente administrada | |
EA201501065A1 (ru) | Содержащая модифицированное лекарственное вещество на основе гемоглобина фармацевтическая композиция для таргетной терапии рака и диагностической визуализации | |
BR112023022451A2 (pt) | Composto triazina substituído | |
PE20170445A1 (es) | Compuestos biciclicos sustituidos | |
BR112023019364A2 (pt) | Composição para geração de imagens de contraste de câncer | |
BR112017022506A2 (pt) | composições compreendendo aminoácidos para uso no tratamento de mucosites em pacientes com neoplasia submetidos a terapia de radiação e / ou quimioterapia | |
BR112019018185A2 (pt) | composição para tratar uma doença de articulação humana, e, kit. | |
BR212015012352U2 (pt) | agulha de transfusão com segurança | |
CL2018000726A1 (es) | Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1 | |
BR112016028177A2 (pt) | seringa | |
BR112022019002A2 (pt) | Uso de extrato de amora para controlar a resposta glicêmica pós-prandial | |
BR112022017466A2 (pt) | Terapia combinada com um inibidor de idh mutante e um inibidor de bcl-2 | |
BR112017015597A2 (pt) | moduladores dos receptores da adenosina a3 |